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Background: Adequate serum Vitamin D levels are necessary to optimise bone
health. Following recent recommendations1, we changed our acceptable range of
serum vitamin D from 19−57 ng/ml to 30−60 ng/ml. We wished to evaluate the
serum levels in our clinic in light of this change.
Method: We used retrospective data from each child’s most recent annual review
between March 2006 and December 2007.
Results: 72 children with recent vitamin D levels were identiﬁed. Median age was
10 years (range 0.9−16.9). 34 were male and 65 (90%) were pancreatic insufﬁcient.
Median serum vitamin D was 25 ng/ml (range 8.8−61). Using our previous criteria,
16 children (22%) had levels below 19 ng/ml. Using the new range, 49 children
(68%) had levels below 30 ng/ml. All but one patient had been prescribed vitamin D
supplementation as per national guidelines (400–800 IU per day).
Median vitamin D in pancreatic sufﬁcient children (29.5 ng/ml) was similar to
pancreatic insufﬁcient children (24.8 ng/ml, p = 0.1). There was no relationship
between vitamin D and lung function. A greater proportion of patients had levels
below 30 ng/ml when taken during winter/spring (29/35, 83%) compared to the
summer/autumn months (19/37, 51%, p = 0.006).
Conclusion: Using the new range, the majority of children had inadequate serum
vitamin D levels, despite apparent adequate supplementation. There appears to be
some seasonal effect. We are collecting prospective data following increased sup-
plementation, including high dose therapy when serum levels are below 20 ng/ml.
Reference(s)
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Background: Vitamin D deﬁciency is increasingly being recognised and treated
in children with CF. However the treatment guidelines are not proven and the
effectiveness of Vitamin D preparations among CF patients is untested.
Objective: To evaluate the effectiveness of daily supplementation of 800 IU Vita-
min D (cholecalciferol/D3) over a period of one year in children with CF.
Methods: During 2005–2006, serum 25(OH)D (Vitamin D) levels were measured
in children with CF. Children who had vitamin D level <75nmol/L (n = 35) were
commenced on an additional daily dose of 800 IU Vitamin D. Repeat vitamin D
levels were measured one year after this intervention and recorded. Vitamin D
levels were measured in the same Month for each child so that seasonal variation
did not inﬂuence the results.
Results: Nineteen boys and 16 girls with mean age 13±0.5 (SE) were involved
in the study. After the year of supplementation serum 25(OH)D levels were
increased in 18 children but overall there was no signiﬁcant improvement (n = 35),
P = 0.75, (CI: −7.42, 5.37). When 11 children who admitted poor compliance (took
supplement <7 days per week) were removed, there was still no improvement in
serum (OH)D levels (n = 24), P = 0.67, (CI: −8.85, 5.77). In the 18 children whose
levels did increase the improvement ranged from 9nmol/L to 18nmol/L (CI).
Conclusion: Although numbers may be small in this study it indicates that current
dosage and method of supplementation with vitamin D in children with CF is
grossly inadequate. Compliance may be one of the major factors causing the poor
response to supplementation, which highlights the urgent need to source a high
strength vitamin D preparation, which would be more acceptable among the CF
population.
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Objective: This was to review the bone density, calcium intake, serum vitamin D
levels, vitamin D supplement dosage and use of steroids in children with CF.
Method: 19 patients with CF, 18 were pancreatic insufﬁcient and 1 pancreatic
sufﬁcient, between the ages of 10 and 16 years completed a 3 day food diary to
assess their calcium intake, had their serum vitamin D level taken and bone density
assessed using a DEXA Scan. The drug history was taken from the medical notes to
assess the steroid intake and the parents asked to report the vitamin D supplement
dosage.
Results: The audit revealed that 81% of our children with CF had suboptimal
serum vitamin D levels but only 5% had frank vitamin D deﬁciency determined
by the serum result. 100% of children were meeting the RNI for calcium and
reported taking 800iu vitamin D daily. 18% had a DEXA Scan z score of less than
−2.0 standard deviations from the norm [a reduced bone mineral density (RBMD)]
and 70% of these children had taken steroids in the last twelve months with 6%
(1 child) having experienced bone fractures. There appeared to be no correlation
between serum vitamin D and bone density.
Conclusions: RBMD exists in our children with CF and this may well be aggrevated
by the use of steriods. This incidence of RBMD is in line with the reported incidence
in adults of 20−30%. Serum vitamin D levels are not achieving the recommended
point of >25ug/l despite the children reportedly taking 800iu per day. Calcium
requirements are achieved.
There is disparity between the recommended dose of vitamin D supplementation
and recommended serum levels. Bone density of children with CF should be
assessed.
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Aim: To assess vitamin D levels among children with CF, to determine the seasonal
variation and ascertain if any relationship exists between vitamin D level and
supplementation (IU), Pancreatic Enzyme Replacement therapy (PERT), (IU/kg),
Age and FEV 1%.
Methods: A retrospective review of Vitamin D from the years 2003–2007 was
obtained from medical records (n = 204 vitamin D levels, taken from 86 patients).
Vitamin D supplementation, PERT, age and FEV1% was obtained from the 86 pa-
tients and compared with their most recent vitamin D level (2006−07). Regression
analysis was carried out and box plots of seasonal variation in Vitamin D were
drawn.
Results: Twenty one per cent and 58% of Vitamin D levels were >75nmol/L
and 50nmol/L respectively. Vitamin D levels varied each Month with the highest
levels seen in August, September and October with median results of 69, 71
and 64 nmol/L respectively. The lowest levels were seen in December, January
and February with medians of 40, 38 and 40nmol/L. No correlation between
Vitamin D levels and vitamin D supplementation, PERT or FEV1% was found
with r of −0.18 (p = 0.119), 0.12 (p = 0.285) and 0.2 (p = 0.072) respectively. There
was a signiﬁcant negative association between Vitamin D level and age (r = −0.37,
p = 0.000).
Conclusion: These results show that low vitamin D levels are prevalent in children
with CF as only 21% of levels were above 75nmol/L. It also highlights the seasonal
variation of Vitamin D. The lack of positive correlation between Vitamin D
Supplementation and Vitamin D levels show that current levels of Vitamin D
supplementation (up to 2000 IU/day) may be inadequate to correct low levels in
all Children with CF and thus an alternative source of vitamin D needs to be
established.
